Abstract：
BACKGROUND: This study aimed to investigate the associations of digital ulcers (DUs) in patients with systemic sclerosis (SSc).
METHODS: This retrospective study investigated the demographic characteristics, specific autoantibodies, organ involvement, and laboratory tests in patients with SSc from our hospital.
RESULTS: This study enrolled 144 patients with SSc. The DU+ group consisted of 15 (10.4%) patients. Patients with SSc having DUs have longer disease duration, higher fibrinogen, higher fibrin degradation product, and lower cholesterol. None of the patients used cholesterol-lowering drugs before onset of DUs. The study also demonstrated a higher prevalence of anti-dsDNA and anti-histone antibodies in patients with SSc with DUs. Anti-dsDNA antibody is a specific antibody for SLE with a specificity of 96-99%. A total of 86.1% (124/144) of patients suffered from diffuse cutaneous SSc, and 28.5% (41/144) of patients suffered from overlap syndrome.
CONCLUSIONS: Our study indicated that patients with SSc with fibrinogen of >2.895 g/L (p = 0.043) and cholesterol of <3.340 mmol/L (p = 0.036), which is equal to 129.258 mg/dL, are at high risk of developing DUs.
METHODS: This retrospective study investigated the demographic characteristics, specific autoantibodies, organ involvement, and laboratory tests in patients with SSc from our hospital.
RESULTS: This study enrolled 144 patients with SSc. The DU+ group consisted of 15 (10.4%) patients. Patients with SSc having DUs have longer disease duration, higher fibrinogen, higher fibrin degradation product, and lower cholesterol. None of the patients used cholesterol-lowering drugs before onset of DUs. The study also demonstrated a higher prevalence of anti-dsDNA and anti-histone antibodies in patients with SSc with DUs. Anti-dsDNA antibody is a specific antibody for SLE with a specificity of 96-99%. A total of 86.1% (124/144) of patients suffered from diffuse cutaneous SSc, and 28.5% (41/144) of patients suffered from overlap syndrome.
CONCLUSIONS: Our study indicated that patients with SSc with fibrinogen of >2.895 g/L (p = 0.043) and cholesterol of <3.340 mmol/L (p = 0.036), which is equal to 129.258 mg/dL, are at high risk of developing DUs.
摘要：
背景：本研究旨在探讨系统性硬化症（SSc）患者数字溃疡（DU）的相关性。
方法：这项回顾性研究调查了人口统计学特征，特异性自身抗体，器官受累,以及我们医院的SSc患者的实验室检查。
结果：本研究纳入144例SSc患者。DU+组由15名(10.4%)患者组成。有DU的SSc患者疾病持续时间较长，更高的纤维蛋白原，较高的纤维蛋白降解产物，降低胆固醇。在DU发作之前，没有患者使用降胆固醇药物。该研究还表明，在患有DU的SSc患者中，抗dsDNA和抗组蛋白抗体的患病率更高。抗dsDNA抗体是SLE的特异性抗体,特异性为96%-99%。共有86.1%(124/144)的患者患有弥漫性皮肤SSc，28.5%(41/144)的患者患有重叠综合征。
结论：我们的研究表明，SSc患者的纤维蛋白原>2.895g/L（P=0.043），胆固醇<3.340mmol/L（P=0.036），等于129.258mg/dl，开发DU的风险很高。
方法：这项回顾性研究调查了人口统计学特征，特异性自身抗体，器官受累,以及我们医院的SSc患者的实验室检查。
结果：本研究纳入144例SSc患者。DU+组由15名(10.4%)患者组成。有DU的SSc患者疾病持续时间较长，更高的纤维蛋白原，较高的纤维蛋白降解产物，降低胆固醇。在DU发作之前，没有患者使用降胆固醇药物。该研究还表明，在患有DU的SSc患者中，抗dsDNA和抗组蛋白抗体的患病率更高。抗dsDNA抗体是SLE的特异性抗体,特异性为96%-99%。共有86.1%(124/144)的患者患有弥漫性皮肤SSc，28.5%(41/144)的患者患有重叠综合征。
结论：我们的研究表明，SSc患者的纤维蛋白原>2.895g/L（P=0.043），胆固醇<3.340mmol/L（P=0.036），等于129.258mg/dl，开发DU的风险很高。
